Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Cervomed Inc (CRVO)

Cervomed Inc (CRVO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 49,241
  • Shares Outstanding, K 6,170
  • Annual Sales, $ 7,140 K
  • Annual Income, $ -2,170 K
  • EBIT $ -10 M
  • EBITDA $ -10 M
  • 60-Month Beta 1.63
  • Price/Sales 6.89
  • Price/Cash Flow N/A
  • Price/Book 1.30

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.65
  • Number of Estimates 3
  • High Estimate -0.35
  • Low Estimate -0.81
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.07%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.75 +18.19%
on 11/26/24
14.62 -37.35%
on 10/31/24
-4.54 (-33.14%)
since 10/25/24
3-Month
7.75 +18.19%
on 11/26/24
20.63 -55.60%
on 09/13/24
-7.51 (-45.05%)
since 08/27/24
52-Week
5.85 +56.58%
on 12/29/23
26.38 -65.28%
on 03/20/24
-0.62 (-6.34%)
since 11/27/23

Most Recent Stories

More News
CervoMed Stock Surges On FDA Orphan Drug Nod For FTD Treatment: Retail Optimism Rekindled

The Orphan Drug status provides CervoMed with several key benefits, including tax credits for clinical trial costs, regulatory assistance, and seven years of post-approval market exclusivity.

IWC : 137.77 (+0.67%)
VXF : 204.50 (-0.11%)
CRVO : 9.08 (+13.78%)
VTI : 297.90 (-0.38%)
IWM : 240.82 (+0.08%)
CervoMed Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for the Treatment of Frontotemporal Dementia

CRVO : 9.08 (+13.78%)
CervoMed Announces Key Senior Leadership Appointments

CRVO : 9.08 (+13.78%)
CervoMed Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

CRVO : 9.08 (+13.78%)
CervoMed Awarded the Prix Galien USA 2024 Prize for Best Startup

CRVO : 9.08 (+13.78%)
CervoMed to Participate in Upcoming Investor Conferences

CRVO : 9.08 (+13.78%)
CervoMed Announces Key Takeaways from Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)

CRVO : 9.08 (+13.78%)
CervoMed to Deliver Oral Presentation at the 8th International Lewy Body Dementia Conference

CRVO : 9.08 (+13.78%)
CervoMed Announces Last Patient Last Visit in Phase 2b RewinD-LB Trial of Neflamapimod for the Treatment of Early-Stage Dementia with Lewy Bodies (DLB)

CRVO : 9.08 (+13.78%)
CervoMed to Present at the 2023 Roth Healthcare Opportunities Conference

/PRNewswire/ -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage company focused on developing treatments for degenerative diseases of the brain, today announced...

CRVO : 9.08 (+13.78%)

Business Summary

CervoMed Inc. is a clinical-stage biotechnology company advancing CNS-focused therapeutics for patients with a range of degenerative diseases of the brain. The Company is currently developing neflamapimod, an investigational orally administered small molecule brain penetrant which inhibits p38MAP kinase...

See More

Key Turning Points

3rd Resistance Point 9.82
2nd Resistance Point 9.36
1st Resistance Point 8.67
Last Price 9.08
1st Support Level 7.52
2nd Support Level 7.06
3rd Support Level 6.37

See More

52-Week High 26.38
Fibonacci 61.8% 18.54
Fibonacci 50% 16.11
Fibonacci 38.2% 13.69
Last Price 9.08
52-Week Low 5.85

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar